Your session is about to expire
What is Axiron
TestosteroneThe Generic name of this drug
Treatment SummaryTestosterone is a hormone that plays an important role in male sexual development. It is used to treat low levels of testosterone in the body, either due to primary hypogonadism or hypogonadotropic hypogonadism. Testosterone works by changing the way genes are expressed, causing the growth and development of masculine sex organs and other male characteristics. It was first isolated from samples in 1935 and has been synthetically created since then.
Androdermis the brand name
Axiron Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Androderm
Testosterone
1995
90
Approved as Treatment by the FDA
Testosterone, commonly known as Androderm, is approved by the FDA for 12 uses including Hypogonadism and Gonadotrophin releasing hormone deficiency .Hypogonadism
Helps manage Idiopathic Hypogonadotropic Hypogonadism
Gonadotrophin releasing hormone deficiency
Helps manage Gonadotrophin releasing hormone deficiency
Puberty, Delayed
Used to treat Puberty, Delayed in combination with Testosterone enanthate
Orchitis
Helps manage Orchitis
Hypergonadotropic Hypogonadism
Helps manage Hypergonadotropic Hypogonadism
Torsion of testis
Helps manage Torsion of testis
Hypothalamo-pituitary disorder
Helps manage Hypothalamo-pituitary disorder
vanishing testis syndrome
Helps manage vanishing testis syndrome
Hypogonadotropic hypogonadism
Orchidectomy
Helps manage Orchidectomy
Breast
Used to treat inoperable, metastatic Breast cancer in combination with Testosterone enanthate
1 to 5 years post-menopausal
Used to treat 1 to 5 years post-menopausal in combination with Testosterone enanthate
Effectiveness
How Axiron Affects PatientsTestosterone is used to help the body grow and develop masculine sex organs and features. It usually only works for a short amount of time (10 to 100 minutes) with normal levels of testosterone in an adult man ranging from 300 to 1000ng/dL. It is important to warn patients about the possible risks of exposing children to testosterone.
How Axiron works in the bodyThe androgen receptor helps the body develop masculine physical traits and characteristics. It is found in the cytoplasm and binds to testosterone and its active metabolite dihydrotestosterone (DHT). This binding causes the receptor to change shape, so it can travel to the nucleus of the cell. Here, it binds to DNA and triggers the production of specific genes. These genes are responsible for the development of masculine sex organs like the prostate and penis, as well as secondary sexual characteristics like facial hair and changes in muscle and fat distribution.
When to interrupt dosage
The prescribed amount of Axiron is based on the diagnosed condition, including Gonadotrophin releasing hormone deficiency, Orchidectomy and Orchitis. The amount of dosage is dependent on the technique of administration featured in the table beneath.Condition
Dosage
Administration
1 to 5 years post-menopausal
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel, Gel - Transdermal, Intramuscular, Injection, solution - Intramuscular, Injection - Intramuscular, Topical, Gel - Topical, Subcutaneous, Pellet, Pellet - Subcutaneous, Patch, Patch - Transdermal, Solution, Solution - Topical, Buccal, Tablet, Tablet - Buccal, Oral, Pellet - Oral, Capsule - Oral, Capsule, Suspension, Suspension - Intramuscular, Nasal, Gel - Nasal, Gel, metered, Gel, metered - Topical, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable, Pellet, implantable - Subcutaneous, Parenteral, Pellet, implantable - Parenteral
vanishing testis syndrome
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel, Gel - Transdermal, Intramuscular, Injection, solution - Intramuscular, Injection - Intramuscular, Topical, Gel - Topical, Subcutaneous, Pellet, Pellet - Subcutaneous, Patch, Patch - Transdermal, Solution, Solution - Topical, Buccal, Tablet, Tablet - Buccal, Oral, Pellet - Oral, Capsule - Oral, Capsule, Suspension, Suspension - Intramuscular, Nasal, Gel - Nasal, Gel, metered, Gel, metered - Topical, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable, Pellet, implantable - Subcutaneous, Parenteral, Pellet, implantable - Parenteral
Orchitis
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel, Gel - Transdermal, Intramuscular, Injection, solution - Intramuscular, Injection - Intramuscular, Topical, Gel - Topical, Subcutaneous, Pellet, Pellet - Subcutaneous, Patch, Patch - Transdermal, Solution, Solution - Topical, Buccal, Tablet, Tablet - Buccal, Oral, Pellet - Oral, Capsule - Oral, Capsule, Suspension, Suspension - Intramuscular, Nasal, Gel - Nasal, Gel, metered, Gel, metered - Topical, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable, Pellet, implantable - Subcutaneous, Parenteral, Pellet, implantable - Parenteral
Puberty, Delayed
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel, Gel - Transdermal, Intramuscular, Injection, solution - Intramuscular, Injection - Intramuscular, Topical, Gel - Topical, Subcutaneous, Pellet, Pellet - Subcutaneous, Patch, Patch - Transdermal, Solution, Solution - Topical, Buccal, Tablet, Tablet - Buccal, Oral, Pellet - Oral, Capsule - Oral, Capsule, Suspension, Suspension - Intramuscular, Nasal, Gel - Nasal, Gel, metered, Gel, metered - Topical, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable, Pellet, implantable - Subcutaneous, Parenteral, Pellet, implantable - Parenteral
Hypogonadism
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel, Gel - Transdermal, Intramuscular, Injection, solution - Intramuscular, Injection - Intramuscular, Topical, Gel - Topical, Subcutaneous, Pellet, Pellet - Subcutaneous, Patch, Patch - Transdermal, Solution, Solution - Topical, Buccal, Tablet, Tablet - Buccal, Oral, Pellet - Oral, Capsule - Oral, Capsule, Suspension, Suspension - Intramuscular, Nasal, Gel - Nasal, Gel, metered, Gel, metered - Topical, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable, Pellet, implantable - Subcutaneous, Parenteral, Pellet, implantable - Parenteral
Gonadotrophin releasing hormone deficiency
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel, Gel - Transdermal, Intramuscular, Injection, solution - Intramuscular, Injection - Intramuscular, Topical, Gel - Topical, Subcutaneous, Pellet, Pellet - Subcutaneous, Patch, Patch - Transdermal, Solution, Solution - Topical, Buccal, Tablet, Tablet - Buccal, Oral, Pellet - Oral, Capsule - Oral, Capsule, Suspension, Suspension - Intramuscular, Nasal, Gel - Nasal, Gel, metered, Gel, metered - Topical, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable, Pellet, implantable - Subcutaneous, Parenteral, Pellet, implantable - Parenteral
Hypothalamo-pituitary disorder
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel, Gel - Transdermal, Intramuscular, Injection, solution - Intramuscular, Injection - Intramuscular, Topical, Gel - Topical, Subcutaneous, Pellet, Pellet - Subcutaneous, Patch, Patch - Transdermal, Solution, Solution - Topical, Buccal, Tablet, Tablet - Buccal, Oral, Pellet - Oral, Capsule - Oral, Capsule, Suspension, Suspension - Intramuscular, Nasal, Gel - Nasal, Gel, metered, Gel, metered - Topical, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable, Pellet, implantable - Subcutaneous, Parenteral, Pellet, implantable - Parenteral
Orchidectomy
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel, Gel - Transdermal, Intramuscular, Injection, solution - Intramuscular, Injection - Intramuscular, Topical, Gel - Topical, Subcutaneous, Pellet, Pellet - Subcutaneous, Patch, Patch - Transdermal, Solution, Solution - Topical, Buccal, Tablet, Tablet - Buccal, Oral, Pellet - Oral, Capsule - Oral, Capsule, Suspension, Suspension - Intramuscular, Nasal, Gel - Nasal, Gel, metered, Gel, metered - Topical, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable, Pellet, implantable - Subcutaneous, Parenteral, Pellet, implantable - Parenteral
Breast
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel, Gel - Transdermal, Intramuscular, Injection, solution - Intramuscular, Injection - Intramuscular, Topical, Gel - Topical, Subcutaneous, Pellet, Pellet - Subcutaneous, Patch, Patch - Transdermal, Solution, Solution - Topical, Buccal, Tablet, Tablet - Buccal, Oral, Pellet - Oral, Capsule - Oral, Capsule, Suspension, Suspension - Intramuscular, Nasal, Gel - Nasal, Gel, metered, Gel, metered - Topical, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable, Pellet, implantable - Subcutaneous, Parenteral, Pellet, implantable - Parenteral
Torsion of testis
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel, Gel - Transdermal, Intramuscular, Injection, solution - Intramuscular, Injection - Intramuscular, Topical, Gel - Topical, Subcutaneous, Pellet, Pellet - Subcutaneous, Patch, Patch - Transdermal, Solution, Solution - Topical, Buccal, Tablet, Tablet - Buccal, Oral, Pellet - Oral, Capsule - Oral, Capsule, Suspension, Suspension - Intramuscular, Nasal, Gel - Nasal, Gel, metered, Gel, metered - Topical, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable, Pellet, implantable - Subcutaneous, Parenteral, Pellet, implantable - Parenteral
Hypergonadotropic Hypogonadism
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel, Gel - Transdermal, Intramuscular, Injection, solution - Intramuscular, Injection - Intramuscular, Topical, Gel - Topical, Subcutaneous, Pellet, Pellet - Subcutaneous, Patch, Patch - Transdermal, Solution, Solution - Topical, Buccal, Tablet, Tablet - Buccal, Oral, Pellet - Oral, Capsule - Oral, Capsule, Suspension, Suspension - Intramuscular, Nasal, Gel - Nasal, Gel, metered, Gel, metered - Topical, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable, Pellet, implantable - Subcutaneous, Parenteral, Pellet, implantable - Parenteral
Hypogonadotropic hypogonadism
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel, Gel - Transdermal, Intramuscular, Injection, solution - Intramuscular, Injection - Intramuscular, Topical, Gel - Topical, Subcutaneous, Pellet, Pellet - Subcutaneous, Patch, Patch - Transdermal, Solution, Solution - Topical, Buccal, Tablet, Tablet - Buccal, Oral, Pellet - Oral, Capsule - Oral, Capsule, Suspension, Suspension - Intramuscular, Nasal, Gel - Nasal, Gel, metered, Gel, metered - Topical, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable, Pellet, implantable - Subcutaneous, Parenteral, Pellet, implantable - Parenteral
Warnings
Axiron ContraindicationsCondition
Risk Level
Notes
suspected pregnancy
Do Not Combine
Breast Cancer
Do Not Combine
Common Axiron Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be increased when combined with Testosterone.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be increased when combined with Testosterone.
Alectinib
Major
The metabolism of Alectinib can be increased when combined with Testosterone.
Aminophylline
Major
The metabolism of Aminophylline can be increased when combined with Testosterone.
Astemizole
Major
The metabolism of Astemizole can be increased when combined with Testosterone.
Axiron Toxicity & Overdose RiskInformation about an overdose of a testosterone product is not readily available. However, if someone overdoses on the injectable form of the drug, they may suffer a stroke. To treat an overdose of testosterone, the product should be stopped and any topical product washed off with soap and water. The patient should also receive symptomatic and supportive treatments.
Axiron Novel Uses: Which Conditions Have a Clinical Trial Featuring Axiron?
A total of 10 active clinical trials are exploring the potential of Axiron to treat Orchitis, Torsion of Testis and Hypothalamic-Pituitary Disorders.Condition
Clinical Trials
Trial Phases
1 to 5 years post-menopausal
0 Actively Recruiting
Hypergonadotropic Hypogonadism
0 Actively Recruiting
Torsion of testis
0 Actively Recruiting
Hypothalamo-pituitary disorder
0 Actively Recruiting
Orchitis
0 Actively Recruiting
Puberty, Delayed
0 Actively Recruiting
Hypogonadism
8 Actively Recruiting
Phase 1, Phase 4, Phase 2, Not Applicable
Gonadotrophin releasing hormone deficiency
1 Actively Recruiting
Phase 1
vanishing testis syndrome
0 Actively Recruiting
Hypogonadotropic hypogonadism
0 Actively Recruiting
Breast
0 Actively Recruiting
Orchidectomy
0 Actively Recruiting
Axiron Reviews: What are patients saying about Axiron?
4Patient Review
8/16/20132Patient Review
1/7/2014 I'm not convinced that this treatment is worth the high price tag. It did improve my symptoms slightly, but caused some skin irritation.
1.7Patient Review
11/11/2015 The application is terrible: pump it into a "cup" and hope it doesn't slosh out while trying to slather it into your armpit, where it starts running down your sides because it takes too long to dry. Stuck it out for a month, progressively bad psychosis, was suicidal by the end. Not ideal for guys who are on total testosterone replacement.
1.3Patient Review
6/10/2016 I started using this treatment three months ago in order to improve my libido, which was a symptom of hypogonadism. I saw no improvement whatsoever and found the application process to be really painful and irritating. I'll be switching to injections as soon as possible.
Patient Q&A Section about axiron
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.Is Axiron a steroid?
"These drugs are anabolic steroids and they can cause harmful physical and psychological effects, especially for women. Women who are exposed to testosterone treatments may develop acne and masculinized characteristics, such as increased body and facial hair."
Answered by AI
Is Axiron still available?
"The FDA has announced that Axiron will no longer be manufactured, effective September 2017. The product is being discontinued for reasons unrelated to safety or efficacy."
Answered by AI
What is the generic name for Axiron?
"Assuming you are asking for a summary:
Testosterone is a drug used in males to treat low testosterone levels. It is available in gel, cream, andpatch forms. Testosterone levels are typically measured via blood tests."
Answered by AI
What is Axiron used for?
"Axiron is a drug used to treat the symptoms of Testosterone Deficiency. It may be used alone or with other medications."
Answered by AI